International Chair of Life Sciences Cheryl Reicin authored an article in The Globe and Mail, discussing how the new capital-gains tax will limit and potentially reverse growth in the Canadian life science and health care sectors. 

Cheryl wrote, “In the life-science sector especially, compensation practices rely heavily on equity compensation programs as young, innovative companies tend to be cash-poor. As a direct result of the planned increase in capital-gains taxes, companies will have no choice but to offset the lost value by offering more stock options and other non-cash incentives to remain competitive.”

Source

The Globe and Mail